In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 and attract ...
GOSSAMER BIO ($GOSS) is expected to release its quarterly earnings data on Friday, March 21st after market close, per Finnhub. Analysts are expecting revenue of ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
Gossamer Bio has a one year low of $0.50 and a one year high of $1.60. The stock has a market cap of $278.72 million, a PE ratio of -3.84 and a beta of 1.81. The firm has a 50 day simple moving ...
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio (GOSS – Research Report), with a price target of $15.00. The company’s shares closed ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback